Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

LCTX vs AGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AGEN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

AGEN Overall Winner 6-Pillar Tally: LCTX 1 – 4 AGEN (1 Tie) Matrix Metrics: LCTX 2 – 8 AGEN

As of Nov 19, 2026, Agenus Inc. (AGEN) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas AGEN carries 54.2/100 (HOLD) at $6.14 (3.7x Forward P/E, 38.9% operating margin).

  • Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. AGEN 54.2/100 HOLD), AGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (38.9% vs. -280.3% operating margin) and revenue trajectory (+4.1% vs. -61.0% YoY).
  • Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1); meanwhile AGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LCTX vs AGEN
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.36β · 79% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.3%), weak momentum, RSI 37
RSI-14: 37.1 · SMA20: $0.98 · SMA50: $0.98
AGEN NASDAQ Head-to-Head Winner
Agenus Inc.
Biological Products, (No Disgnostic Substances)
$6.14
-4.06% 1D
Market Cap $289.6M
TTM Revenue $34M
Forward P/E 3.7x
Beta / 30D Vol 1.58β · 77% Vol
Unified Composite Score
54.2 / 100 HOLD
Tech 48.0 Fund 49.0 Flow 70.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 41
RSI-14: 40.7 · SMA20: $6.70 · SMA50: $7.28

6-Pillar Scorecard Institutional Category Breakdown (LCTX 1 – 4 AGEN)

Columns: Metric · LCTX · AGEN
1. Valuation Multiples AGEN
Forward P/E 30.7x 3.7x
Trailing P/E 30.7x 27.8x
PEG Ratio 10.64x 1.44x
EV / Revenue 16.3x 8.3x
2. Growth & Scale AGEN
Revenue Growth (YoY) -61.0% +4.1%
Earnings Growth (YoY) +0.0% -99.0%
TTM Revenue (USD) $11M $34M
Market Cap $212.1M $289.6M
3. Profitability & Quality AGEN
Gross Margin -95.0% N/A
Operating Margin -280.3% 38.9%
Net Profit Margin 16.2% 30.8%
Return on Equity (ROE) 4.3% -1278.8%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$24M -$35M
Cash Flow Margin N/A -103.7%
Net Cash / Leverage $35M Net Cash $9.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AGEN
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 896.2% (100th %ile) 167.5% (31st %ile)
Put/Call OI Skew 1.10x (Balanced) 0.04x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LCTX (2) vs AGEN (8)
Institutional Metric LCTX AGEN Criterion Row Edge
Market Capitalization
Scale
$212.1M $289.6M Larger Scale AGEN
Trailing P/E Ratio
Valuation
30.7x 27.8x Lower Multiple AGEN
Forward P/E Ratio
Valuation
30.7x 3.7x Lower Multiple AGEN
Revenue Growth (YoY)
Growth
-61.0% +4.1% Higher Growth AGEN
Operating Margin (TTM)
Profitability
-280.3% 38.9% Higher Margin AGEN
Net Profit Margin
Profitability
16.2% 30.8% Higher Margin AGEN
Return on Equity (ROE)
Capital Efficiency
4.3% -1278.8% Higher ROE LCTX
52-Week Range Position
Momentum
4% ($1–$2) 45% ($3–$10) Stronger Trend AGEN
Beta / 30D Volatility
Risk Regime
1.36β · 79% Vol 1.58β · 77% Vol Lower Realized Risk AGEN
Unified Institutional Score
Composite Signal
58.9 / 100 (HOLD) 54.2 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$11M $34M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-95.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.64x PEG · 16.3x EV/Rev 1.44x PEG · 8.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($35M Net Cash) -$35M ($9.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AGEN +9.76 pp
LCTX: -13.82% · AGEN: -4.06%
3M Horizon Tie
LCTX: -24.07% · AGEN: -24.1%
6M Horizon AGEN +132.18 pp
LCTX: -37.88% · AGEN: +94.3%
1Y Horizon AGEN +98.82 pp
LCTX: -53.67% · AGEN: +45.15%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LCTX Revenue AGEN Revenue LCTX Op. Margin AGEN Op. Margin Margin Leader
FY2018 $0M $40M -837.9% -336.6% AGEN
FY2019 $0M $150M -1106.0% -46.7% AGEN
FY2020 $0M $90M -1448.4% -133.0% AGEN
FY2021 $0M $300M -1133.6% 8.7% AGEN
FY2022 $10M $100M -153.2% -183.0% LCTX
FY2023 $10M $160M -276.5% -102.1% AGEN
FY2024 $10M $100M -226.1% -116.4% AGEN
FY2025 $10M $110M -251.6% -17.7% AGEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LCTX BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 896.2%
IV Percentile 100th %ile
Put/Call OI Skew 1.10x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AGEN BREAKDOWN
36d in phase · OBV NEUTRAL
Current IV 167.5%
IV Percentile 31st %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $289.6M market capitalization and 38.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LCTX vs AGEN Key Questions & Quantitative Answers

As of Nov 19, 2026, Agenus Inc. (AGEN) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas AGEN carries 54.2/100 (HOLD) at $6.14 (3.7x Forward P/E, 38.9% operating margin). Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. AGEN 54.2/100 HOLD), AGEN captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (38.9% vs. -280.3% operating margin) and revenue trajectory (+4.1% vs. -61.0% YoY). Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.1); meanwhile AGEN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AGEN leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with AGEN at +4.1% YoY revenue growth and -99.0% YoY earnings growth on $34M TTM revenue (N/A gross margin, 38.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LCTX cumulative revenue shifted +0.0% while AGEN shifted +175.0%. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AGEN.

AGEN screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin), whereas AGEN trades at 3.7x Forward P/E, 27.8x Trailing P/E, 1.44x PEG, and 8.3x EV/Revenue (-103.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus AGEN (-1278.8% ROE) capital efficiency.

In options market volatility and institutional positioning, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk). By comparison, AGEN carries 167.5% implied volatility (31st %ile, Balanced (25th–60th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.58β · 77% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.